BR112022012199A2 - Forma de dosagem com péletes de melatonina de liberação sustentada - Google Patents

Forma de dosagem com péletes de melatonina de liberação sustentada

Info

Publication number
BR112022012199A2
BR112022012199A2 BR112022012199A BR112022012199A BR112022012199A2 BR 112022012199 A2 BR112022012199 A2 BR 112022012199A2 BR 112022012199 A BR112022012199 A BR 112022012199A BR 112022012199 A BR112022012199 A BR 112022012199A BR 112022012199 A2 BR112022012199 A2 BR 112022012199A2
Authority
BR
Brazil
Prior art keywords
dosage form
pellets
melatonin
sustained release
release melatonin
Prior art date
Application number
BR112022012199A
Other languages
English (en)
Portuguese (pt)
Inventor
M Shah Syed
Hassan Daniel
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestle Sa filed Critical Nestle Sa
Publication of BR112022012199A2 publication Critical patent/BR112022012199A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112022012199A 2020-01-17 2021-01-15 Forma de dosagem com péletes de melatonina de liberação sustentada BR112022012199A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062962574P 2020-01-17 2020-01-17
PCT/EP2021/050770 WO2021144403A1 (en) 2020-01-17 2021-01-15 Dosage form with sustained release melatonin pellets

Publications (1)

Publication Number Publication Date
BR112022012199A2 true BR112022012199A2 (pt) 2022-09-13

Family

ID=74285447

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012199A BR112022012199A2 (pt) 2020-01-17 2021-01-15 Forma de dosagem com péletes de melatonina de liberação sustentada

Country Status (8)

Country Link
US (2) US11723862B2 (https=)
EP (1) EP4090315A1 (https=)
JP (2) JP2023510223A (https=)
CN (1) CN114901256A (https=)
AU (1) AU2021207284B2 (https=)
BR (1) BR112022012199A2 (https=)
CA (1) CA3163378A1 (https=)
WO (1) WO2021144403A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024079125A1 (en) 2022-10-14 2024-04-18 Société des Produits Nestlé S.A. Sustained release melatonin compositions
CN116172979B (zh) * 2023-02-15 2024-10-15 浙江贝灵生物医药有限公司 一种褪黑素缓释小丸及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003043A1 (en) * 1993-07-26 1995-02-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Sustained release oral compositions containing melatonin
JP4641696B2 (ja) * 1999-09-30 2011-03-02 大塚製薬株式会社 消化管下部溶解性コーティング製剤
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
KR100501827B1 (ko) 2002-09-24 2005-07-20 한국화학연구원 다층 코팅법을 이용한 멜라토닌 함유 타게팅 약물 전달 기구
US20070298117A1 (en) * 2006-06-23 2007-12-27 The Procter & Gamble Company Compositions and kits comprising a melatonin component and a chondroprotective component
US20070299127A1 (en) * 2006-06-23 2007-12-27 The Procter & Gamble Company Compositions and kits comprising a melatonin component and an omega-3-fatty acid component
US20080171085A1 (en) * 2007-01-11 2008-07-17 Natrol, Inc. Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration
WO2011160003A1 (en) * 2010-06-17 2011-12-22 Antioxidant Superfoods, Inc. Improved health characteristic chewy or gummy candy confection
WO2012103411A2 (en) * 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US20120315337A1 (en) 2011-06-07 2012-12-13 Shah Syed Multiparticulate 5-htp compositions and related methods
ITMI20112042A1 (it) * 2011-11-10 2013-05-11 Eratech S R L Polvere da ricostituire prima dell'uso comprendente melatonina e preparazione iniettabile ottenibile da tale polvere.
CA3013472A1 (en) * 2016-02-11 2017-08-17 Biogen Ma Inc. Pharmaceutical bead formulations comprising dimethyl fumarate
WO2017192843A1 (en) * 2016-05-06 2017-11-09 Physician's Seal, LLC Valerian composition and related methods
GR1009541B (el) 2018-02-26 2019-06-07 Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας & Αναπτυξης Α.Ε. Ποσιμα φαρμακευτικα διαλυματα που περιλαμβανουν μελατονινη
CN113490491A (zh) * 2019-01-18 2021-10-08 雀巢产品有限公司 固体微粉化褪黑激素组合物

Also Published As

Publication number Publication date
US20210220264A1 (en) 2021-07-22
US11723862B2 (en) 2023-08-15
AU2021207284A1 (en) 2022-06-09
EP4090315A1 (en) 2022-11-23
WO2021144403A1 (en) 2021-07-22
US20230045118A1 (en) 2023-02-09
US12558310B2 (en) 2026-02-24
JP2025169319A (ja) 2025-11-12
JP2023510223A (ja) 2023-03-13
CA3163378A1 (en) 2021-07-22
AU2021207284B2 (en) 2026-02-12
CN114901256A (zh) 2022-08-12

Similar Documents

Publication Publication Date Title
EA201400972A1 (ru) Лекарственные формы немедленного высвобождения с защитой от несанкционированного применения
BR112022012199A2 (pt) Forma de dosagem com péletes de melatonina de liberação sustentada
MX2015012589A (es) Formulaciones farmaceuticas resistentes a la manipulacion.
CL2016001031A1 (es) Forma de dosificación de liberación inmediata que evita el abuso, que comprende partículas de núcleo recubiertas y una matriz; su uso para preparar un medicamento útil para prevenir, aliviar o aminorar un nivel de dolor y para prevenir el abuso de un fármaco analgésico narcótico, entre otros.
NI201300054A (es) Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas
MX2021008247A (es) Combinacion de dextrometorfano y bupropion para el tratamiento de depresion.
ES2530681T3 (es) Composiciones farmacéuticas flotantes de liberación controlada
BR112012005969A2 (pt) forma de dosagem sólida oral contendo nanopartículas e processo de formulação da mesma usando gelatina de peixe
BR112017008993A2 (pt) métodos e composições especificamente para o tratamento de transtorno de déficit de atenção
EA201390981A1 (ru) Разрушающаяся во рту таблетка
BRPI0502466A (pt) forma de dosagem sólida para ingrediente ativo lábil a ácidos
UY30636A1 (es) Composision farmaceutica de liberacon modificada de un musculo relajante y un aine
CR20170142A (es) Composiciones farmacéuticas resistentes al abuso
BR122021012549B8 (pt) Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva
CO2022018623A2 (es) Composiciones farmacéuticas que contienen sustancias liberadoras de enterocinas en múltiples formas de dosificación combinadas con agentes gelificantes
EA201170784A1 (ru) Гранулы тамсулозина для фиксированной комбинации
CO2026000726A2 (es) Una forma farmacéutica sólida de dosificación bucodispersable de safinamida
CO6150129A2 (es) Formas segmentadas de dosificacion farmaceutica
BR112015023381A2 (pt) composição de liberação imediata de sovaprevir, composição de sovaprevir de 200 mg, núcleo de comprimido de sovaprevir e comprimido de sovaprevir revestido
MX2013005187A (es) Composicion farmaceutica y forma galenica y forma galenica a base de drodedarona y su procedimiento de preparacion.
JP2023510223A5 (https=)
MD4877B1 (ro) Compoziţie farmaceutică şi comprimat oral de S-adenozilmetionină cu eliberare întârziată
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
EA201170880A1 (ru) Таблетка с контролируемым высвобождением с малой дозой активного вещества

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]